CTLA4 and neoplasm: For example, preclinical evidence has shown that ultrasound treatments designed to cause thermal or mechanical damage to tumours can provide some anti-cancer benefit when combined with a number of immunotherapies including anti-CTLA-4 and/or anti-PD-1 antibodies, CD40 stimulation and toll-like receptor agonists [16–20].